← Oncology Approval Tracker

FDA DECISION ·

Kisqali + fulvestrant

ribociclib with fulvestrant · Novartis

FDA approvalNew or expanded indicationBreast cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adults with HR-positive, HER2-negative advanced or metastatic breast cancer; ribociclib with fulvestrant as initial endocrine-based therapy or after progression on endocrine therapy.

LAMPGEN ANALYSIS

Why it matters

This supplement broadened the fulvestrant combination from its earlier postmenopausal population to the labeled adult population.

What research teams should watch

Record menopausal status and the need for concurrent gonadal suppression; retain the endocrine history and ECG and blood test schedule.

PRIMARY RECORDS

Sources